Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent inherited nephropathy. To date, therapies alleviating the disease have largely focused on targeting abnormalities in renal epithelial cell signaling. ADPKD has many hallmarks of cancer, where targeting T cells has brought novel therapeutic interventions. However, little is known about the role and therapeutic potential of T cells in ADPKD. Here, we used an orthologous ADPKD model, Pkd1 p.R3277C (RC), to begin to define the role of T cells in disease progression. Using flow cytometry, we found progressive increases in renal CD8 + and CD4 + T cells, correlative with disease severity, but with selective activation of CD8 + T cells. By immunofluorescence, T cells specifically localized to cystic lesions and increased levels of T-cell recruiting chemokines (CXCL9/CXCL10) were detected by qPCR/in situ hybridization in the kidneys of mice, patients, and ADPKD epithelial cell lines. Importantly, immunodepletion of CD8 + T cells from one to three months in C57Bl/6 Pkd1 RC/RC mice resulted in worsening of ADPKD pathology, decreased apoptosis, and increased proliferation compared to IgG-control, consistent with a reno-protective role of CD8 + T cells. Thus, our studies suggest a functional role for T cells, specifically CD8 + T This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). observed intra-and interfamilial phenotypic heterogeneity, ranging from in utero onset 21, 22 to adequate renal function at old age, 23 exceeds genic effects, 3, 24 suggesting that additional, nongenetic factors contribute to disease progression. Further, the functional role of the PKD1 and PKD2 proteins, polycystin-1 and polycystin-2, while extensively studied, remains elusive, leaving many open questions regarding the mechanisms that drive cystogenesis. [25] [26] [27] [28] Although ADPKD historically has been considered a "neoplasia in disguise," 29 the significant similarities between ADPKD and cancer have been rediscovered more recently. 30 In fact, many of the cancer hallmarks as defined by Hanahan and Weinberg 31 are applicable to ADPKD (e.g., sustained proliferation, 12,30,32 genomic instability, 33-35 deregulated cellular energetics, 36,37 and inflammation/avoiding immune destruction [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] ). Importantly, interstitial inflammation has been reported in human patients with ADPKD, as well as in animal models of the disease. 40 In concordance with an inflammatory response, increased levels of pro-inflammatory cytokines, such as monocyte chemoattractant protein-1 and tumor necrosis factor-α, were detected in cyst fluid of patients with ADPKD, and antiinflammatory therapies have been shown to attenuate disease progression in animal models. [38] [39] [40] Furthermore, macrophage infiltration can be observed in orthologous and nonorthologous ADPKD models at advanced disease stage, 41-43 and a few reports show CD4 + T cells, mast cells, and neutrophils in the interstitium of patients with ADPKD. [44] [45] [46] Additionally, historic data showed that murine PKD models raised in germ-free 
environments present with milder cystic disease, 47 suggesting a role for the immune system in PKD. In fact, it was shown that M2-like macrophages can promote cyst growth in murine models of autosomal recessive PKD (ARPKD) and ADPKD and that their depletion slows renal and hepatic cystogenesis. 41, 42, 48 However, to date, no research in the literature addresses the role of the adaptive immune system in ADPKD initiation and progression.
Targeting adaptive immunity has become a central focus in developing new therapeutic approaches in multiple malignancies. 49, 50 In many cancers, increased numbers of tumorinfiltrating T cells are associated with better prognosis, 51 consistent with a role for these cells in inhibiting tumor progression. However, the role of different T-cell subtypes is complex because of their heterogeneity. 52 As such, different populations have either protumorigenic (e.g., regulatory T cells [Tregs] ) or antitumorigenic (e.g., CD8 + T cell) roles. Additionally, cancers have developed multiple cellular and molecular pathways to suppress T-cell functions. Strategies targeting the interaction of specific T cells with cancer cells have shown recent clinical success, leading to FDA approval of checkpoint inhibitors that target the interactions of programmed cell death protein-1 (PD-1) with its ligand PD-L1, resulting in reactivation of antitumor CD8 + T cells. 53, 54 The progress made in the field of cancer research, specifically the function of T cells in tumorigenesis, may yield new ideas and avenues for ADPKD research. Thus, an essential first step forward is to understand the role of T cells in ADPKD progression.
Here, we characterized T-cell subpopulations in an orthologous mouse model of ADPKD that reproduces critical features of the human disease, including a slow rate of progression. We found that T cells increase in correlation with disease severity and localize specifically to cystic lesions. Importantly, our results define a functional role for CD8 + T cells in inhibiting ADPKD progression, highlighting the potential to adapt cancer immunotherapy strategies to ADPKD.
RESULTS

Renal T-cell numbers are increased in the C57Bl/6 Pkd1 RC/RC model compared with wild type
The homozygous Pkd1 p.R3277C (Pkd1 RC/RC ) 55 model genetically and physiologically mimics human ADPKD. It harbors a knock-in mutation that mimics a hypomorphic allele identified in ADPKD families 56 and presents over time in the C57Bl/6 background with slowly progressive disease with moderate increases in percent kidney weight/body weight (%KW/BW), renal cystic/fibrotic area (index), chronic inflammation (increased renal interleukin-6/decreased interleukin-10 levels), as well as mild renal function decline (Supplementary Figure S1 ; Supplementary Table S1 ). To evaluate how the cystic microenvironment (CME), specifically T cells, differ between C57Bl/6 wild type (WT) and Pkd1 RC/RC mice and to correlate changes in the adaptive immune system profile with cystogenesis progression, we used flow cytometry analysis of renal single cell suspensions and analyzed mice at 3, 6, and 9 months of age. In Pkd1 RC/RC C57Bl/6 mice at 3 and 6 months, when the cystic disease is mild/moderate, respectively, we detected a statistically significant increase in immune cells (CD45 + ) and T cells (T-cell receptor β + [TCRβ + ]) in Pkd1 RC/RC compared with WT mice, but the most striking increase occurred at 9 months of age, the investigated time point at which PKD is most severe (Figure 1a Table S1) . Importantly, as shown by immunofluorescence, T cells (CD3 + , CD4 + , CD8 + ) specifically localized around cystic lesions even at mild stages of cystogenesis (3 months) when the global increase of T-cell number in the kidney was modest (Figure 1e and f; Supplementary Figure S2 ). At 9 months a more diffuse increase of T cells was notable by immunofluorescence, characterized by increased localization to noncystic areas, likely accounting for the striking increase in T-cell number at 9 months observed by flow cytometry (Figure 1b and e) . This finding likely reflects the adaptive immune system's response to increasing tubular atrophy and interstitial expansion/inflammation that can be observed in 9-month-old Pkd1 RC/RC C57Bl/6 mice, despite the slowly progressive/mild disease (Supplementary Figure S1C) . Importantly, the increase in T-cell numbers between C57Bl/6 WT and Pkd1 RC/RC mice was specific to kidney disease, as no changes were observed in spleens (Supplementary Figure S3) .
Increases in T-cell numbers correlate with PKD severity
The Pkd1 RC/RC model presents with varying disease severity in different mouse strains, being mildest in the C57Bl/6 and significantly more severe in the 129/S6 and Balb/c backgrounds as measured by percent kidney weight/body weight, renal cystic/fibrotic area (index), renal function, and cytokine levels (Supplementary Figure S1 ; Supplementary Table  S1 ). Interestingly, among these strains, only renal cyst size but not cyst number varies significantly, suggesting that variances in the rate of cyst progression rather than cyst initiation drive disease severity differences, indicative of a microenvironmental role in disease pathology (Supplementary Figure S1F and G).
To evaluate whether T-cell number increases correlate to disease severity, we performed comparable experiments in 129/S6 and Balb/c Pkd1 RC/RC mice as for the C57Bl/6 background. We observed similar changes in the adaptive immune system in 129/S6 and Balb/c Pkd1 RC/RC mice ( Figure 2; Supplementary Figure S4) . However, the overall increase in CD45 + and T-cell subpopulations (TCRβ + , CD8 + , and CD4 + ) compared with WT was much larger in the 129/S6 and Balb/c Pkd1 RC/RC models than in the C57Bl/6 Pkd1 RC/RC model, correlating with the more severe disease in these strains. This outcome was notable by flow cytometry (Figure 2a Table S1 ).
T-cell recruiting cytokines/chemokines are upregulated in ADPKD
To evaluate the rise in T-cell numbers mechanistically, we performed quantitative polymerase chain reaction for interferon (IFN)-γ, a cytokine produced by activated T cells, 57 and T-cell recruiting chemokines (Cxcl9, Cxcl10 58, 59 ). Levels of all 3 gene products were increased in the kidney as disease progressed (Figure 3a Table S1 ). In cancer, CXCL9 and CXCL10 induce lymphocyte infiltration and lead to suppression of tumor growth because of the infiltration of primarily CD8 + and Th 1 CD4 + T cells. 60, 61 Upon further investigation, in situ hybridization of Balb/c Pkd1 RC/RC renal sections revealed that Cxcl9/Cxcl10 are produced primarily in cystic regions, and co-immunofluorescence staining for CD3 showed that T cells co-localize near the cystic regions that produce Cxcl9/Cxcl10 (Figure 3d) . From a closer examination of these data, it is apparent that while multiple cells may be producing these chemokines, significant numbers of epithelial cells stained positive, highlighting that the cystic epithelium plays an active role in T-cell recruitment (Figure 3d , inset).
To determine if this mechanism of T-cell recruitment is relevant to human disease, we performed in situ hybridization for CXCL9 and CXCL10 on human ESRD ADPKD and ARPKD formalin-fixed-paraffin-embedded kidneys. As in mice, CD3 + T cells co-localized to regions with high CXCL9/CXCL10 levels, and both of these chemokines were produced by the cystic epithelium (Figure 3e ). In both ADPKD and ARPKD, we observed similar increases in CXCL9/CXCL10 levels and overall T-cell infiltrate to cystic regions, which were significantly higher compared with normal human kidney tissue.
Because CXCL9/CXCL10 production by cancer cells has been reported previously and predicts tumor outcome, 62, 63 we wanted to determine if renal epithelial cells can produce CXCL9 and CXCL10 in vitro. Using quantitative polymerase chain reaction on normal renal cortical tubular epithelial (RCTE) 64 cells (WT for PKD1/PKD2) and 9-12 64 cells (PKD1 null) treated with recombinant human IFN-γ for 24 hours, we were able to show an increase of CXCL9 and CXCL10 mRNA (Figure 4a and b) . Interestingly, 9-12 cells had a significantly higher basal level of both cytokines compared with RCTE cells (Figure 4a and b). IFN-γ has previously been shown to have antiproliferative effects on cancer cells via a signal transducer and activator of transcription 1 mechanism. 65, 66 To explore whether IFN-γ has antiproliferative effects on the ADPKD cystic epithelium, RCTE and 9-12 cells were treated with IFN-γ for 72 hours and cell proliferation was assessed by cell count. The 9-12 cells showed decreased rates of proliferation, whereas there was no effect on normal RCTE cells (Figure 4c ), suggesting that IFN-γ produced by T cells can inhibit cyst growth by directly acting on cystic epithelial cells.
CD8 + T cells are predominantly activated in Pkd1 RC/RC mice
We next examined cell-surface markers of T-cell activation (CD44 [expressed after antigen exposure and a switch from naive to effector or memory T cells] 67 and CD69 [expressed after antigen interaction] 68 ) to better understand which T-cell subtype may play a predominant role in cystogenesis. We detected significant increases in activated CD8 + but not CD4 + T cells in C57Bl/6 Pkd1 RC/RC mice compared with WT ( Figure 5 ; Supplementary   Table S1 ), suggesting a more prominent role of CD8 + T cells in ADPKD progression. Similarly, CD8 + T-cell activation also correlated with disease severity and was more pronounced in the faster progressing 129/S6 and Balb/c Pkd1 RC/RC mice compared with the C56Bl/6 Pkd1 RC/RC model ( Figure 5 ; Supplementary Table S1 ).
Interestingly, in WT mice, we detected fewer renal CD45 + and TCRβ + cells in strains with more severe disease when harboring the Pkd1 p.R3277C mutation (129/S6 or Balb/c vs.
C57Bl/6, Supplementary Figure S5A ). Furthermore, C57Bl/6 mice had significantly higher levels of CD8 + T cells compared with the other 2 strains, whereas the numbers of CD4 + T cells were similar in all 3 strains (Supplementary Figure S5B and C). Previous studies have documented differences in the immune system profile between C57Bl/6 and Balb/c strains, and these differences partially accounted for the variable responses to infection. 69, 70 Hence, the difference in CD8 + T cells between WT strains may partially explain the variation in severity of ADPKD across the different strains of Pkd1 RC/RC mice.
CD8 + T cells play an anticystogenic role in ADPKD
In cancer models, activated CD8 + T cells constrain tumor growth. Based on the predominant activation of CD8 + T cells, the observed increase of IFN-γ correlative with their activation, and their lower numbers in strains with more severe disease, we hypothesized that depleting this population would result in enhanced disease severity. We therefore tested this hypothesis initially in the C57Bl/6 strain, in which an increase in cystogenesis would be easier to detect compared with the more severe models, using antibody depletion. We depleted CD8 + T cells twice a week by i.p. injection of anti-CD8 antibody (control: IgG) into C57Bl/6 Pkd1 RC/RC mice from 1 to 3 months. Even though CD8 + depletion was incomplete after 3 weeks of treatment (Supplementary Figure S6) , 3-month-old Pkd1 RC/RC anti-CD8-treated mice showed increased disease burden by gross kidney anatomy and histology, a significant increase in percent kidney weight/body weight, fibrotic index, and cyst size, but no change in cyst number (Figure 6a-f; Supplementary Table S2; blood urea nitrogen and plasma creatinine levels were not significantly altered). Interestingly, anti-CD8-treated mice presented with a significant decrease in terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling (TUNEL) positive cells and a significant increase in proliferating cell nuclear antigen (PCNA) positive cells within the dilated/cystic epithelium (Figure 6g-j) , supporting our in vitro RCTE versus 9-12 IFN-γ stimulated cell counting experiment (Figure 4c ). Hence these data support a functional role for CD8 + T cells in inhibiting fibrosis and ADPKD cyst progression through increasing apoptosis/decreasing proliferation, but not cyst initiation. Follow-up experiments showed that anti-CD8 depletion in the rapidly progressive 126/S6 Pkd1 RC/RC model did not affect disease progression (Supplementary   Table S2 ). This finding may be due to fundamental strain differences such as lower basal numbers in CD8 + T-cell numbers, or it may be a related consequence of more rapidly progressing cysts altering the CME composition, resulting in diminished interactions with the adaptive immune system.
The microenvironment of early-onset compared with typical adult-onset ADPKD is predominantly characterized by an increase in macrophages
Lastly, we examined changes in immune cells in an early-onset ADPKD model. In utero or early-onset ADPKD occurs in <3% of ADPKD cases and genetically is often associated with a complex PKD1/PKD2 genotype. 18 To mimic this, we used the C57Bl/6 Pkd1 p.R3277C model crossed with the C57Bl/6 Pkd1 del2 model 71 (Pkd1 RC/− ), which presents with rapidly progressive cystogenesis leading to death at approximately postnatal day 25 55 compared with the Pkd1 RC/RC model, which, dependent on the strain, may die at 12 months or older. At postnatal day 20, we analyzed the adaptive immune system as previously described. We noted, as with the Pkd1 RC/RC model, an overall increase in immune cells; however, this increase was 2.3-fold more pronounced, likely correlating with increased disease severity (Figure 7a) . Interestingly, the CME profile was strikingly different between both models. Whereas T-cell numbers increased in both (Figure 7b ), the Pkd1 RC/− CME was highly inflamed, as characterized by a marked increase in macrophages (CD64 + ; Figure 7c ). This increase predominantly drove the overall increase in CD45 + cells, as evident by the contribution of macrophages to the CD45 + cell population being significantly increased and the contribution of T cells decreased (Figure 7d and e). This striking increase in macrophages suggests a potential key role of this cell type in rapidly progressive disease, as previously reported in other rapidly progressive PKD models used for preclinical trials. 41, 42 It also is characteristic of a highly inflamed microenvironment, which has been associated with more severe human disease, characterized by lower renal function and higher total kidney volume compared with typical ADPKD. 72, 73 Correlatively, macrophage numbers have been shown to increase by histology in patients with ARPKD or advanced ADPKD 42, 74 ; however, detailed analyses at different ADPKD stages are lacking.
DISCUSSION
Therapeutic strategies in ADPKD have largely focused on targeting dysregulated growth pathways in cystic epithelial cells, which are presumably the direct consequence of mutations in the PKD1 or PKD2 genes. This is analogous to targeted therapies directed against oncogenic drivers in cancer. However, in cancer, it has become clear that progression of tumors does not only involve oncogenic signaling pathways but also entails complex interactions between the cancer cells and the surrounding tumor microenvironment. It has been suggested that similar interactions are important in ADPKD progression. 30 The results of our study demonstrate, for the first time, changes in adaptive immune cell populations and a functional role for CD8 + T cells in ADPKD progression. Using an orthologous mouse model that mimics the slowly progressive disease of humans, we identified a rise in both renal CD8 + and CD4 + T cells that correlated with disease severity, with predominant activation of CD8 + T cells. Importantly, even at mild stages of disease when the observed rise in T-cell numbers, as measured by flow cytometry, were modest, T cells specifically localized to cystic lesions and only increased in the kidney, suggesting that specific interactions between the cystic epithelium and T cells results in recruitment and activation of T cells. Our data support a model where T-cell recruitment occurs as a secondary event to cyst initiation/progression, presumably as a result of neoantigen presentation caused by genomic instability within the cystic epithelium. 33, 34 Rapidly advancing cyst growth, as observed in the 129/S6 or Balb/c Pkd1 RC/RC mice, likely is associated with an overall greater instance of genomic instability, upregulation of the neoantigen presentation pathway, and hence increased T-cell recruitment/CD8 + T-cell activation, as our data confirm. Recruited/activated T cells secrete IFN-γ, resulting in increased production of CD8 + T-cell attracting chemokines (CXCL9/10) by cells within the CME and the cystic epithelium, causing further recruitment of CD8 + T cells in a positive feedback loop. This ultimately reflects the adaptive immune system's attempt to eliminate cystic epithelia and suggests an anticystogenic role for CD8 + T cells. We confirmed CXCL9/ CXCL10 production by CME cells and the tubular epithelium in ADPKD/ARPKD patient samples and show in vivo that CD8 + T cells halt cyst progression by modulating tubular apoptosis and proliferation.
However, as has been shown in cancer, 75 recruited T cells may not always be fully capable of eliminating cyst growth because of simultaneous activation of immunosuppressive pathways, which inhibit the function of anti-tumor CD8 + cells. This may explain the continuous growth of cysts even as CD8 + T-cell numbers increase. Targeting these immunosuppressive pathways can result in reactivation of T cells and immunoelimination of tumors. 76, 77 One such pathway is the immune checkpoint PD-1/PD-L1, 76 where PD-1 is expressed on activated T cells and PD-L1 is expressed on other cell types (epithelial cells, cancer cells, and inflammatory cells). 78 Binding of PD-L1 to PD-1 inactivates T-cell responses and leads to an exhausted phenotype. Treatment with blocking antibodies results in reactivation of T cells. 50, 79 This approach has resulted in FDA approval of checkpoint inhibitors in multiple types of cancer. While repurposing of FDA-approved checkpoint inhibitors to ADPKD may not be achievable immediately because of known renal toxicities, 80 it is important to note that in multiple clinical cancer trials, checkpoint inhibitors have shown lasting tumor elimination even after stopping therapy. 81, 82 Thus modifications to dosage/treatment protocols using these agents may be feasible for ADPKD, where prolonged efficacy is needed.
Our data further highlight that caution is warranted when choosing an ADPKD model to study the common, slow-progressing adult-onset form. For example, we observed that CD8 + T-cell depletion did not promote cystogenesis in the rapidly progressive 129/S6 Pkd1 RC/RC mice as it did in the C57/Bl6 Pkd1 RC/RC model. This outcome may occur because the rapidly advancing disease leads to activation/deactivation of different pathways compared with slowly progressive disease or because differences in the CME, for example, the notably low CD8 + T-cell numbers in 129/S6 mice, blunt various therapeutic approaches. Correlatively, in rapidly progressing mouse models mimicking early-onset ADPKD, it appears that changes in inflammatory cells, for example, macrophages, are more robust than changes in T cells, whereas in the slower progressing model, T cells appear to predominate. This finding could reflect the time required to develop a mutational burden that results in neoantigens recognized by the adaptive immune system. Further, our data do not show a significant increase in renal macrophages at 3 months of age in C57Bl/6 Pkd1 RC/RC mice (Figure 7 ), as has been published for other rapidly progressive models 41, 42 ; however, further time points and the other strains need to be studied to clearly determine whether renal macrophages rise in the Pkd1 RC/RC model. Thus, when wanting to test the translatability of immunotherapeutic approaches to alleviate typical ADPKD, choice of model will be critical.
More research will need to be performed to better elucidate the significance of increased CD4 + T-cell numbers observed in our models. Currently it is difficult to predict the potential functional impact resulting from this increase because CD4 + T cells have multiple subtypes (Tregs, Th 1 , Th 2 , Th 17 ) with opposing effects on effector CD8 + T-cell function. Specifically, Th 1 cells upregulate antigen presentation and as such regulate the duration and magnitude of CD8 + T-cell response, whereas Tregs increase immunosuppressive cytokines and inhibit CD8 + T-cell function. 52 Thus immunodepleting all CD4 + may not reveal the role of these distinct populations. We further appreciate that even CD8 + T cells present with varying phenotypes, which we have not addressed here and requires further studies.
In summary, our data are the first to describe an increase in renal T cells associated with disease severity, a specific activation of CD8 + T cells, and a functional role of these cells in inhibiting cystogenesis. Hence, we suggest that immunotherapies leading to reactivation of T cells may represent a novel therapeutic strategy. Because such agents, including immune checkpoint inhibitors, are FDA approved for multiple cancers and specifically act on CD8 + T-cell reactivation, it raises the possibility of repurposing these drugs for use in people with ADPKD.
CONCISE METHODS
Full methods are available in the Supplementary Methods.
Mouse models
We used the C57Bl/6, 129/S6, and Balb/c Pkd1 RC/RC model and the C57Bl/6 Pkd1 RC/− model, as previously published. 55, 71 WT control subjects were obtained from Jackson Laboratory, Bar Harbor, ME or Taconic Biosciences Inc, Rensselaer, NY.
Human samples
De-identified human ADPKD/ARPKD and normal human kidney formalin-fixed, paraffinembedded sections were obtained from the Kansas PKD Research and Translational Core Center (P30 DK106912) at the University of Kansas Medical Center.
Kidney function analyses
Blood urea nitrogen was measured using the QuantiChrom Urea Assay Kit (BioAssay Systems, Hayward, CA) according to the manufacturer's protocol. Plasma creatinine concentration was analyzed with high-performance liquid chromatography-tandem-mass spectrometry (HPLC-MS/MS; Applied Biosystems 3200 Q TRAP, Foster City, CA). 83 
Histomorphometric analysis
Cystic index, cyst size, and cyst number were analyzed using a custom-built NIS-Elements AR v4.6 macro (Nikon, Minato, Tokyo, Japan). Fibrotic area was analyzed from picrosirius red-stained kidney sections, visualized using an Olympus BX41 microscope (Olympus Corporation, Center Valley, PA) with a linear polarizer.
Cell culture
All cell lines have been previously described. 64, 84 Cells were grown in either DMEM/F12 +L-glutamine, 15nM HEPES (Corning Inc., Corning, NY; RCTE, 9-12) or RPMI-1640 +L-glutamine (Corning; HCC827) supplemented with 10% fetal bovine serum (VWR International, Radnor, PA) and 1% penicillin-streptomycin (Corning).
Proliferation assay
RCTE and 9-12 cells were treated for 72 hours with IFN-γ (100 ng/ml) or phosphatebuffered saline solution (control) and subsequently counted using the Cellometer Auto T4 (Nexcelom Bioscience, Lawrence, MA).
Immunofluorescence Labeling/Quantification
Tissues were prepared for IF labeling as previously described 55 with the following modification: Autofluorescence quenching with 0.1% Sudan Black in 70% ethanol, 2-hour antigen retrieval at 100 °C, washes in tris-buffered saline solution and Tween 20 (TBST). Terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling staining was performed according to the manufacturer's protocol (In Situ Cell Death Detection Kit, TMR red; Sigma-Aldrich Inc., St. Louis, MO). Quantification was performed using NIS-Elements AR v4.6 (Nikon). Antibody details can be found in the Supplementary Methods.
Quantitative polymerase chain reaction
Renal tissue RNA was isolated from a small piece of flash-frozen tissue using the RNeasy Plus Mini Kit (Qiagen, Germantown, MD) and cDNA was synthesized using the qScript XLT cDNA SuperMix (Quantabio, Beverly, MA). For human cell RNA, RCTE, 9-12, and HCC827 cells were treated with IFN-γ (100 ng/ml) or phosphate-buffered saline solution (control) for 24 hours prior to RNA isolation. Quantitative polymerase chain reaction was performed using the PowerSYBER PCR Master Mix (Applied Biosystems) on a CFX96 Real-Time System (Bio-Rad Laboratories, Hercules, CA). Primer details can be found in the Supplementary Methods.
Single cell suspension
Dissected kidney and spleen tissue were mechanically dissociated and digested in a mixture containing DMEM/F12, Liberase TL, and DNaseI at 37 °C for 30 minutes. Dissociation was completed using an 18G needle and quenched using FA3 buffer. Cells were passed through a 100 μm filter, underwent a red blood cell lysis, and then were passed through a 70-#x03BC;m filter.
Flow cytometry
T-cell panel protocol.-The single cell suspension was blocked in anti-mouse CD16/ CD32 on a rocker for 15 minutes at 4 °C. Fix viability dye and conjugated antibodies were then added, and cells were incubated in the dark on a rocker at 4 °C for 45 minutes. Cells were resuspended in FA3 buffer and ran on the Gallios Flow Cytometer Machine (Beckman Coulter, Brea, CA). Antibody details can be found in the Supplementary Methods. Renal single cell suspensions of wild type (WT) and Pkd1 RC/RC 129/S6 and Balb/c mice were analyzed in the same manner as for the C57Bl/6 strain. A more rapid increase, notably at younger ages, of CD45 + (a), T-cell receptor β + (TCRR + ) (b), CD8 + (c), and CD4 + (d) cells was observed in the Pkd1 RC/RC compared with WT mice of these strains with more rapidly progressive disease. Immunofluorescence quantification of CD3 + T cells shows a larger number of positive cells near cystic lesions from a very young age on and only a modest increase over time, correlating with the high cystic burden these animals present with at 3 months (e). Data are represented as mean ± SEM, and a nonparametric MannWhitney test was performed on the data. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. N ≥ 6 mice per group (one-half females, one-half males). Quantitative polymerase chain reaction (qPCR) of RNA isolated from whole kidney pieces of wild type (WT) and Pkd1 RC/RC mice showed increased levels of interferon (IFN)-γ, a cytokine secreted by CD8 + T cells (a) and chemokines known to recruit T cells (b, Cxcl9 and c, Cxcl10) when comparing Pkd1 RC/RC with WT mice in both the mild C57Bl/6 and the severe Balb/c background (relative cytokine/chemokine levels may not correlate to disease severity because RNA was isolated from only a small kidney piece, ignoring the nonhomogeneous nature of the disease). (d) Representative in situ hybridization images of 3-month-old Balb/c mice. In WT mice, staining for Cxcl9/Cxcl10 (red) with immunofluorescent co-staining for CD3 (green) and E-cadherin (white) showed no Cxcl9/ Cxcl10 expression in microenvironmental cells or renal tubules; 4',6-diamidino-2-phenylindole [DAPI] = blue. Little Cxcl9/Cxcl10 was detected in noncystic regions of Pkd1 RC/RC mice; however, much higher levels of the chemokines were observed in cystic regions where significant numbers of T cells accumulate. Interestingly, both chemokines were also produced by the cystic epithelium and not only by cells within the cystic microenvironment (insets). (e) T-cell infiltration to cystic regions and CXCL9/CXCL10 production by microenvironmental cells and tubular epithelium (insets) were confirmed in human formalin-fixed, paraffin-embedded (FFPE) tissue. Very few T cells (CD3 = green) were infiltrating normal human kidneys (NHKs), and only low levels of CXCL9/CXCL10 (in situ = red) could be detected within the microenvironment or epithelium (E-cadherin = white; 4',6-diamidino-2-phenylindole [DAPI] = blue). As for Pkd1 RC/RC mice, the number of renal T cells were significantly increased in ADPKD/ARPKD patient tissue versus NHK and located predominantly to cystic regions. Here also, significant levels of both chemokines could be detected in the microenvironment and tubular epithelium. Staining of positive and negative control probes for in situ staining are shown. Data are represented as mean ± SEM, and a nonparametric Mann-Whitney test was performed on the data. *P ≤ 0.05; **P ≤ 0.01. N ≥ 6 mice per group (one-half females, one-half males). Bar = 50 μm. ARPDK, autosomal recessive polycystic kidney disease. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org. Wild type (WT) and Pkd1 RC/RC mice were aged to 3,6, and 9 months and flow cytometry of a renal single cell suspension was used to assess differences in activation of CD8 + and CD4 + T cells at varying disease stages. In all 3 strains, CD8 + T cells were preferentially activated based on the T-cell activation markers CD44/CD69 at early disease stages. Comparably, CD4 + T cells did not show an increase in activation relative to WT at any disease stage. Importantly, CD8 + T cells were significantly more activated in 129/S6 and Balb/c ADPKD mice, correlative with their higher disease burden. Data are represented as mean ± SEM, and a nonparametric Mann-Whitney test was performed on the data. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. N ≥ 6 mice per group (one-half females, one-half males). with an increase in CD45 + cells compared with wild type (WT); however, the fold increase is more pronounced in the rapidly progressive disease (a). Although T-cell numbers increase in both models (b), the increase in macrophage numbers account for the majority of the increase in CD45 + cells in the Pkd1 RC/− model (c,d,e). Thus these data indicate that the microenvironment in the Pkd1 RC/− model is highly inflamed, with macrophages being likely one of the key players in disease progression. Further, the adaptive and innate immune system may have a different interplay and role in cystogenesis in the rapid versus slow model of ADPKD. Data are represented as mean ± SEM, and a nonparametric MannWhitney test was performed on the data. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. N ≥ 8 mice per group (one-half females, one-half males).
